BCRX logo

BCRX
Biocryst Pharmaceuticals Inc.

36,596
Mkt Cap
$1.61B
Volume
6.06M
52W High
$11.31
52W Low
$6.00
PE Ratio
-156.45
BCRX Fundamentals
Price
$7.40
Prev Close
$7.62
Open
$7.65
50D MA
$7.34
Beta
0.97
Avg. Volume
3.73M
EPS (Annual)
-$0.43
P/B
-4.02
Rev/Employee
$777,089.66
Loading...
Loading...
News
all
press releases
Rice Hall James & Associates LLC Sells 179,891 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
Rice Hall James & Associates LLC trimmed its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 8.7% in the third quarter, according to the company in its most recent...
MarketBeat·15d ago
News Placeholder
More News
News Placeholder
Alane Barnes Sells 21,773 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 21,773 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price...
MarketBeat·18d ago
News Placeholder
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
Assenagon Asset Management S.A. reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 14.6% during the 3rd quarter, according to its most recent filing with the...
MarketBeat·22d ago
News Placeholder
Q4 Earnings Estimate for BCRX Issued By HC Wainwright
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a report issued on...
MarketBeat·25d ago
News Placeholder
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen ratings firms that are currently covering the...
MarketBeat·28d ago
News Placeholder
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today?
The FDA has approved the use of Orladeyo, an oral drug, for children aged 2–12 with a rare genetic disorder.
Stocktwits·30d ago
News Placeholder
Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
Hood River Capital Management LLC purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the...
MarketBeat·1mo ago
News Placeholder
BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd.
Russell Investments Group Ltd. increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 326.1% during the 2nd quarter, according to its most recent filing with...
MarketBeat·1mo ago
News Placeholder
JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
JPMorgan Chase & Co. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 48.7% during the 2nd quarter, according to its most recent 13F filing with the...
MarketBeat·1mo ago
News Placeholder
BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2,103.7% in the 2nd quarter, according to the company in its most recent...
MarketBeat·1mo ago
<
1
2
...
>

Latest BCRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.